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TA*p63 and GTAp63 achieve tighter transcriptional
regulation in quality control by converting an
inhibitory element into an additional
transactivation domain
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Christian Münch 2,4,5 and Volker Dötsch 1,4
Abstract
The p53 homolog p63 plays important roles in development of epithelial tissues and quality control in germ cells.
These two functions are executed by two distinct isoforms of p63. They are created by different promotors resulting in
isoforms having either an N-terminal transactivation domain (TAp63) or a truncated form (ΔNp63). In addition to these
two N-terminal isoforms a third one with an even longer N-terminus, named TA*p63, has been found. A fourth N-
terminal isoform, GTAp63, that closely resembles TA*p63 was discovered in male germ cells where it is involved in
genetic quality control. Here, we characterize TA*p63α and GTAp63α and show that their N-terminal extensions
stabilize the closed and only dimeric conformation adopted by the shorter TAp63α protein. Both proteins can be
activated by the two kinases Chk2 and CK1 resulting in the open tetrameric state. In this conformation, the N-terminal
extension acts as an additional transactivation domain enhancing transcriptional activity. Through this mechanism, the
difference in transcriptional activity between the repressed and the active state of the protein gets enhanced relative
to TAp63α. Finally, we show by mass spectrometry that TA*p63α is expressed in the breast cancer cell line Sum159 at
the protein level together with mutant p53. Upon doxorubicin treatment, TA*p63α gets activated, providing a
potential new tool to ﬁght cancer.
Introduction
Sequencing of the human genome has identiﬁed
~23,000 open reading frames, which is signiﬁcantly lower
than the number of genes initially estimated and lower
than the number found in other, more primitive organ-
isms, e.g., Daphnia pulex, which has ~31,000 genes1. At
the protein level, however, the complexity of the human
proteome is enhanced by splicing events as well as the use
of alternative promotors and translation start sites. These
processes create isoforms with different activities. By tis-
sue speciﬁc isoform expression the genome encoded
protein functions are vastly expanded. One example for
such an assignment of tissue speciﬁc functions to indivi-
dual isoforms is the family of the tumor suppressor p53
with its three members p53, p63, and p73. Each of the
three proteins exists in several isoforms created by the
combination of different promotors producing various N-
termini and C-terminal splicing events2,3. The tissue
speciﬁc function of individual isoforms is best understood
for p63. The ΔNp63α isoform is expressed in the basal
layer of stratiﬁed epithelial tissues such as skin, where it is
involved in regulation of proliferation and differentiation
of keratinocytes4,5. It is characterized by the replacement
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of the ﬁrst 69 amino acids (aa) of full length TAp63α with
a 14 aa isoform unique peptide due to the use of an
alternative promotor2. Inactivation of this isoform in a
mouse model results in severe developmental defects such
as limb truncations, lack of a multi-layered skin and other
epithelial structures4,5.
The second p63 isoform for which a speciﬁc cellular
function has been identiﬁed is TAp63α, which includes
the full length N-terminal transactivation domain (TAD).
This isoform is highly expressed in oocytes where it serves
as a genetic quality control factor6,7. Mammalian oocytes
get arrested in prophase of meiosis I in which they are
stored in primordial follicles for extended periods of time.
In resting oocytes, TAp63α adopts an inactive, closed and
only dimeric conformation8,9. Upon detection of DNA
double strand breaks it gets activated adopting an active,
open and tetrameric conformation that triggers oocyte
death via the expression of the two BH3-only proteins
NOXA and PUMA10,11. This activation requires the
consecutive action of the priming kinase Chk212, phos-
phorylating a single serine in TAp63α and the executioner
kinase CK1 which phosphorylates four more residues13.
During the initial cloning of p63 a third N-terminal
variation, called TA*p63, was reported2. TA*p63 is cre-
ated by yet another translation start site that adds 39 aa
N-terminally to the TA domain. In transactivation (TA)
assays in Saos2 cells on a p21 promotor construct
TA*p63α is even more transcriptionally repressed than
TAp63α2. Furthermore, it was found that in testis of
humans and great apes an isoform is expressed that is N-
terminally extended as well. This isoform named GTAp63
was created by the integration of the long terminal repeats
(LTR) of the human endogenous retrovirus 9 (ERV9)
about 15 million years ago14. GTAp63α is suggested to be
the counterpart of TAp63α in male testes, responsible for
insuring the genomic integrity. Upon DNA damage, the
isoform can be activated via caspase cleavage in its C-
terminus, which removes the transactivation inhibitory
domain (TID)15. However, in the absence of genotoxic
stress, GTAp63α is inactive, although it is highly and
constitutively expressed in unstressed spermatogenic
precursors. While the expression in spermatogenic pre-
cursors deﬁnes the tissue speciﬁc function for GTAp63α,
no such biological function was so far reported for the
TA* isoform. Recently, however, a mutation in the TA*
speciﬁc domain of p63 was identiﬁed in a patient showing
limb truncations, providing for the ﬁrst time a link
between this particular isoform and its biological function
(will be reported in a separate manuscript). In addition, it
has been reported that mutations in the TA* speciﬁc
peptide occur in some cancer patients (https://cancer.
sanger.ac.uk/cosmic, http://www.cbioportal.org/). Here
we describe our investigations of the molecular mechan-
isms that regulate the transcriptional activity of TA*p63α
and GTAp63α as the basis for understanding their speciﬁc
function.
Results
The N-terminal elongation of TA*p63α and GTAp63α leads
to a further stabilization of the kinetically trapped dimeric
conformation
The sequences deﬁning the TA*p63 and
GTAp63 speciﬁc N-termini can each be divided into two
subdomains: While the C-terminal 18 aa of both peptides
are identical (called in the following GTA* peptide) the N-
terminal sequences diverge (called TA* and GTA pep-
tides). Figure 1 provides an overview of the different p63
isoforms, the primary sequences of the TA*p63 and
GTAp63 speciﬁc N-termini as well as the different tran-
scription start sites.
In earlier studies we had shown that inhibition of the
transcriptional activity of TAp63α is mechanistically
based on the formation of a closed and only dimeric
state with decreased afﬁnity to both the DNA6,8 and
coactivators such as p30016. To investigate if TA*p63α
and GTAp63α adopt a closed, dimeric conformation as
well, we expressed both isoforms and TAp63α as
control in H1299 cells and analyzed their oligomeric
state by Blue-Native (BN)-PAGE. Figure 2a shows that
all three forms are present as closed dimers. Size
exclusion chromatography (SEC) analysis conﬁrmed
this ﬁnding (Supplementary Fig. S1). These results
suggest that the transcriptional activity of TA*p63α
and GTAp63α is regulated via their oligomeric state
similarly to TAp63α.
Cellular TA assays in Saos-2 and H1299 cells with
overexpressed proteins show that the activity of TA*p63α
and GTAp63α is even lower than the activity of TAp63α
(ref. 2, Fig. 2b, c and Supplementary Fig. S2a–f). As a
control experiment, we veriﬁed that TA*p63α and
GTAp63α are both localized in the nucleus to exclude the
hypothesis that the low transcriptional activity is caused
by changes in the cellular localization (Supplementary Fig.
S2g). Previously we have shown that artiﬁcially high
overexpression levels of TAp63α result in the formation
of a small fraction of the tetrameric and active con-
formation resulting in measurable transcriptional activ-
ity17. The lower activity of the two N-terminally elongated
isoforms of p63 could be the result of a higher thermo-
dynamic stability of the closed dimeric state. To investi-
gate this question we performed a TA titration
experiment by transfecting Saos-2 cells with increasing
amounts of DNA (Fig. 2d–g). For TAp63α, a strong
correlation between promotor induction and protein level
is observed, whereas TA*p63α and GTAp63α show no
increase in activity with rising protein levels. This suggests
that the N-terminal extensions contribute to an additional
stabilization of the dimeric and inactive state.
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In p63, the TAD consists of a single helix16 that is cri-
tical for stabilization of the dimeric state9. Mutating the
three aa F16A, W20A, and L23A (FWL mutant) in
TAp63α disrupts the closed state and triggers the for-
mation of an open tetrameric conformation8. We hypo-
thesized that stabilization of the dimer by the N-terminal
extensions in the TA* and GTA isoforms could result in a
higher stability even in the FWL mutants. Analyzing the
FWL mutant of TAp63α by SEC experiments showed the
expected tetrameric state (reference8 and Fig. 3a). In
contrast, the FWL mutants of TA*p63α and GTAp63α
exhibited a signiﬁcant dimeric fraction, further conﬁrm-
ing a stabilizing effect of the N-terminal sequences
(Fig. 3b, c).
The tetrameric state of TAp63α is the thermo-
dynamically most stable one, while the dimeric state is a
kinetically trapped and only metastable conformation9.
Phosphorylation in the sequence directly preceding the
TID15 at the C-terminus of TAp63α functions as a
trigger to overcome this kinetic barrier and converts p63
into the thermodynamically preferred tetramer via a
spring-loaded activation mechanism9,12,13. Kinetically
trapped states can be converted into a thermo-
dynamically more stable state not only by their natural
trigger (phosphorylation in case of p63) but also by
slight destabilization using temperature, pH, or chemi-
cal denaturants18,19. In earlier experiments, we have
shown that relatively low concentrations of urea are
sufﬁcient to convert TAp63α into the open tetrameric
state without affecting the fold of the single domains9.
We incubated the three p63α isoforms with different
urea concentrations followed by analysis on BN-PAGE.
Figure 3d (and Supplementary Fig. S3) shows that for
TAp63α the transition occurs at a distinctively lower
urea concentration compared to TA*p63α and
GTAp63α. These data clearly reveal that the inactive
and dimeric conformations of TA*p63α and GTAp63α
are more stable than the corresponding state of
TAp63α, caused by a further stabilization by the N-
terminal elongations.
Activation of TA*p63α and GTAp63α upon
chemotherapeutic agents
In oocytes, TAp63α is activated upon DNA damage,
caused by e.g., genotoxic stress, via a phosphorylation
dependent mechanism including the kinases Chk2 and
CK1. We wanted to test if the more stable TA*p63α and
GTAp63α dimers can be activated via Chk2 and CK1 as
well. To activate the DNA damage response pathway we
treated transfected U2OS and H1299 cells expressing
wild-type (wt) TA*p63α or GTAp63α with 10 µM dox-
orubicin (Dox) for 6 h. As a control, we used the S582/
S583A mutants, which remove the Chk2 priming site
preventing tetramerization13. Figure 4a, b (and Supple-
mentary Fig. S4a, b) demonstrate that treatment with Dox
activates all three isoforms to adopt tetrameric states and
that the S582/583A mutations prevent this activation also
for TA*p63α and GTAp63α. Tetramerization can also be
prevented by treatment with the Chk2 inhibitor (BML-
277, Merck) or the CK1 inhibitor (PF670462,
Fig. 1 Exons encoding the N-terminal p63 isoforms, domain architecture as well as oligomeric conformation of p63 isoforms. a Testis
speciﬁc GTAp63 is encoded by an upstream exon, named U1, originating from retroviral LTR insertion. mRNA splicing fuses these exons directly to
the exon 2, on which the GTA*peptide and the N-terminal part of TAD are located, in this way skipping exon 1. TA*p63 is encoded on exon1. Main
splicing events are illustrated by solid lines, less frequently splicing by dotted lines, start codons are indicated by arrows. b Amino acid sequences of
the N-terminal p63 isoforms of the corresponding exons, start codons are indicated by arrows. c Domain architecture and oligomeric conformation
of p63 isoforms. GTAp63 and TA*p63 possess an N-terminal elongation compared to TAp63, comprising the TA*- or GTA-peptide, respectively, and
the common GTA*-peptide, whereas the residual domains are shared by all three isoforms. ΔNp63 possess a truncated transactivation domain. The C-
terminal β- and γ-isoforms are created via alternatively splicing. Only the inactive state of TAp63α has a dimeric oligomeric conformation, all other
TAp63 and ΔNp63 isoforms show a tetrameric conformation
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Sigma–Aldrich), further suggesting that activation of
TA*p63α and GTAp63α follows the same mechanism as
TAp63α13 (Fig. 4c).
Despite this qualitative similarity of the activation
mechanism observed for all three isoforms, quantitative
differences exist. An analysis of the tetramer/dimer ratio
revealed that TA*p63α and GTAp63α show a signiﬁcant
population of the dimeric state following treatment with
Dox while TAp63α is almost completely converted into
tetramers (Supplementary Fig. S4c). Measuring
tetramerization kinetics showed a similar behavior. While
TAp63α becomes partly tetrameric already after 1 h of
treatment, TA*p63α and GTAp63α start to become tet-
rameric between 2 h and 4 h and do not reach the high
tetramer/dimer ratio seen with TAp63α (Supplementary
Fig. S4c).
Transactivation potential of TA*p63 and GTAp63
Earlier results have implied that the TA* speciﬁc N-
terminus can also partially inhibit the transcriptional
Fig. 2 Oligomeric conformation and transactivation potential of TA*p63α and GTAp63α. a BN-PAGE analysis of myc-tagged TAp63α, TA*p63α,
and GTAp63α. Three hundred nanogram expression vector carrying the p63 gene were transiently transfected in H1299 cells (12-well plate). Cells
were harvested 24 h after transfection. Migration of the different oligomeric states is indicated by T (tetramer), D (dimer), and M (monomer). For all
three isoforms only dimers are detectable. Western blots were performed with an anti-myc antibody (4A6, Merck). b Transactivation (TA) assay of
TAp63α, TA*p63α and GTAp63α wt, on the p21 promotor. p53 was used as positive control. Hundred nanogram of each plasmid (pcDNA3, pGL3 and
pRL-CMV) were transiently transfected in Saos-2 cells (12-well plate). Cells were harvested 24 h after transfection and assay was performed. Bars
represent the mean value of the biological triplicate, error bars represent the standard deviation (SD), crosses represent the mean value of the
technical replicates (c) SDS-PAGE followed by immunoblotting for myc-tagged TAp63α, TA*p63α, GTAp63α, and p53 protein levels of the TA assay
performed on p21 promotor in Saos-2 cells (Fig. 2b). GAPDH was used as loading control. d, e TA titration assay of TA*p63α and GTAp63α in
comparison to TAp63α on the p21 promotor. Hundred nanogram of pGL3 and pRL-CMV and increasing amount of p63 DNA (10 ng, 25 ng, 50 ng,
100 ng, 150 ng) were transiently transfected in Saos-2 cells. Empty vector was added to a total amount of 350 ng DNA for transfection (12-well plate).
Cells were harvested 24 h after transfection and assay was performed. Protein levels were determined by western blotting. Fold induction is indicated
with white bars, relative protein level with blue colored bars. The protein level for the highest DNA amount of TAp63α was set to 1. Dots represent
protein level of each biological triplicate. f, g SDS-PAGE followed by western blotting for myc-tagged TAp63α, TA*p63α and GTAp63α protein level in
the TA titration assay performed on the p21 promotor in Saos-2 cells (Fig. 2c, d). GAPDH was used as loading control
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activity of isoforms with the short γ-C-terminus2. As
these isoforms are unable to form a closed dimeric state,
the mechanism of inhibition must be different from that
observed in TA*p63α. To address this question we
investigated the inﬂuence of the N-terminal peptides on
the transcriptional activity in open, constitutively tet-
rameric β- and γ-isoforms (Fig. 5a and Supplementary
Fig. S5a–c). We could not detect a signiﬁcant difference
in transcriptional activity on the p21 promotor, how-
ever, noticed that the protein level of TA*p63 and
GTAp63 was lower compared to TAp63 (Supplemen-
tary Fig. S5a). To further relate the promotor activity to
the protein level we performed a TA titration experi-
ment (Fig. 5b–d). For this assay, it is important to work
below saturation levels, which in case of TAp63γ was
unfortunately reached already at low DNA concentra-
tions. The experiment showed that the two N-terminal
isoforms were not less active than TAp63, thus, the N-
terminal peptides have no inhibitory effect on con-
stitutively tetrameric isoforms of p63. In contrast, the
ratio of the fold induction and protein concentration
suggests that the speciﬁc transcriptional activity of the
TAp63* and GTAp63 proteins is higher than the tran-
scriptional activity of TAp63.
Fig. 3 The novel isoforms show a higher kinetic stability in their dimeric state compared to TAp63α. a–c SEC analysis of TAp63α, TA*p63α and
GTAp63α FWL expressed in rabbit reticulocyte lysate. Lysates were applied on a Superose 6 PC 3.2/30 column. Fractions were collected, analyzed and
quantiﬁed via western blot. The sum of the intensities of all fractions corresponds to 100%. Experiments were performed ﬁve times, error bars indicate
SD. d Urea BN-PAGE followed by western blotting for myc-tagged TAp63α, TA*p63α and GTAp63α. Two nanogram expression vector carrying the
p63 gene were transiently transfected in H1299 cells (10 cm dish). Cells were harvested 24 h after transfection. Lysates were incubated with different
urea concentrations on ice and applied on the gel. Migration of the different oligomeric states is indicated by D (dimer) and M (monomer).
Monomers appear on the gel due to the intrinsic kinetically instability of the p63 tetramerization domain39
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Based on this result we hypothesized that in an open,
tetrameric state the TA* and GTA sequences might
actually enhance transcriptional activity, potentially by
acting as additional transactivation domains. Secondary
structure predictions using Phyre2 server20 indeed display
helical conformations for the TA*, GTA, and GTA*
peptides (Supplementary Fig. S6a). In helical wheel pro-
jections of the corresponding regions, large hydrophobic
residues are located on the same site of the predicted
helices similar to the FWL motif in the TAD (Supple-
mentary Fig. S6b). For the TA* peptide, these residues are
Y18* and F22*, for the GTA-peptide W9′, F12′, V15′ and
for the common GTA* sequence W31* and Y35* (TA*
numbering).
Further analyzing the sequences with the “9 aa-
transactivation domain” prediction tool (http://www.
med.muni.cz/9aaTAD/)21 showed matches for all three
sequences ﬁtting to most of the criteria (Supplementary
Fig. S6c). To experimentally investigate these predictions
we mutated the residues most likely important for
transactivation to alanines and investigated their inﬂuence
on the transactivation potential of TAp63γ, TA*p63γ, and
GTAp63γ, each carrying the FWL mutations. As expected
TAp63γ FWL is inactive due to the importance of these
Fig. 4 The kinases Chk2 and CK1 are able to phosphorylate and activate TA*p63α and GTAp63α like TAp63α, however, the high tetramer/
dimer ratio of TAp63α cannot be reached. a, b BN-PAGE and phosphoshift SDS-PAGE analysis of wt and Chk2 priming site mutants (S582/S583A)
followed by western blotting for myc-tagged TA*p63α and GTAp63α in comparison to TAp63α. Three hundred nanogram expression vector carrying
the p63α gene were transiently transfected in U2OS cells (12-well plate). The next day, cells were treated with 10 µM Dox for 6 h. Migration of the
different oligomeric states is indicated by T (tetramer), D (dimer), and M (monomer). The upper and lower panels in b show the same data with
additional contrast enhancement in the lower panel. c BN-PAGE and phosphoshift SDS-PAGE analysis of H1299 cells lysate stably expressing either
myc-tagged TAp63α, TA*p63α, or GTAp63α. Western blot analysis was carried out using an anti-myc antibody (4A6, Merck). Cells were pre-incubated
with increasing Chk2 (BML-277, Merck) or CK1 inhibitor (PF670462, Sigma–Aldrich) concentrations (5, 25, 50 µM) for 1 h. Afterwards, 10 µM Dox was
added and cells were harvested 6 h later. Migration of the different oligomeric states is indicated by T (tetramer), D (dimer), and M (monomer).
Vinculin was used as loading control. Protein levels loaded on BN-PAGE were adjusted to equal p63 amounts by prior western blot analysis. SDS-
PAGE to detect phosphoshifts were not input adjusted
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three aa for interaction with p30016, while the two other
FWL mutants still show distinct induction of the pro-
motor. Only simultaneous mutation of the additional two
motifs predicted in the TA*/GTA and GTA* peptides
leads to a completely inactive protein (Fig. 5e and Sup-
plementary Fig. S6d, e).
Fig. 5 Transactivation potential of constitutively tetrameric TA*p63 and GTAp63 isoforms and its correlation with p300 Taz2 domain
interaction. a TA assay of C-terminal TA*p63 and GTAp63 isoforms in comparison to TAp63 C-terminal isoforms on the p21 promotor. p53 wt was
used as positive, the p53 R175H mutant as negative control. Hundred nanogram of each plasmid (pcDNA3, pGL3 and pRL-CMV) were transiently
transfected in Saos-2 cells (12-well plate). Cells were harvested 24 h after transfection and assay was performed. b, c TA titration assay of TA*p63γ and
GTAp63γ compared to TAp63γ on the p21 promotor. Hundred nanogram of pGL3 and pRL-CMV and increasing amount of p63 DNA (10 ng, 25 ng,
50 ng, 100 ng, 150 ng) were transiently transfected in Saos-2 cells. Empty vector was added to a total amount of 350 ng DNA for transfection (12-well
plate). Cells were harvested 24 h after transfection and assay was performed. Protein levels were determined via western blotting. Fold induction is
indicated with white bars, relative protein level with blue colored bars. The protein level of the highest DNA amount of TAp63α was set to 1. Dots
represent protein level of each biological triplicate. (d) SDS-PAGE followed by western blotting for myc-tagged TAp63γ, TA*p63γ and GTAp63γ
protein level in the TA titration assay performed on p21 promotor in Saos-2 cells. GAPDH was used as loading control. p63 isoforms were detected
with the p63 antibody ab124762 (Abcam) for sensitivity reasons. e TA assay of FWL and potential new TA motif mutants to alanine in the N-terminus
of the TA*/GTAp63 isoforms (TA*p63: Y18* F22*, W31* Y35*; GTAp63:.W9′ F12′ V15′, W29′ Y33′) on the p21 promotor. p53 wt was used as positive
control, the p53 R175H mutant as negative control. Hundred nanogram of each plasmid (pcDNA3, pGL3 and pRL-CMV) was transiently transfected in
Saos-2 cells (12-well plate). Cells were harvested 24 h after transfection and assay was performed. Bars represent the mean value of the biological
triplicate, error bars represent SD, crosses represent mean value of the technical replicates. f Fluorescence anisotropy experiment with the Taz2
domain of p300 and either N-terminal ﬂuorescein-tagged TA*-GTA*- (1*-39*) or GTA-GTA*- (1′-37′) peptide. A peptide concentration of 100 nM was
used for each measuring point with increasing concentration of p300 Taz2 domain
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The FWL motif in the TAD binds to the Taz2 domain
of the co-activator p300 with a sub-µM KD (0.196 ±
0.022 µM)16. We investigated the interaction of the Taz2
domain with the N-terminal peptides by ﬂuorescence
anisotropy measurements. The Taz2 domain interacts
with the TA*-GTA* and GTA-GTA* peptides with KD
values of 13.18 ± 0.93 µM and 4.79 ± 0.24 µM, respectively
(Fig. 5f). The afﬁnity of these peptides is 75- and 25-fold
lower than the afﬁnity of the TA domain; however, the
overall afﬁnity of tetrameric p63 to p300 will be enhanced
by the presence of these additionally interacting
sequences.
Expression of TA*p63α in the triple-negative epithelial
breast cancer cell line Sum159
p63 is rarely found mutated in tumors; however, over-
expression of ΔNp63α has been reported in head and
neck squamous cell carcinoma22 where its high expres-
sion level seems to be a driving force. Occasionally
TAp63α is reported to be present in cancer cells as well.
In a recent investigation of triple-negative breast cancer
tissue, both ΔNp63 and TAp63 were found to be asso-
ciated with different tumor characteristics23. TAp63α
expression was correlated with androgen receptor and
BRCA1/2 wild-type status and predicts a better patient
survival rate. Similarly, expression of TAp63α in cervical
squamous cell carcinomas showed a positive correlation
with patient survival24. Currently no antibodies are
available that could distinguish TAp63 from TA*p63. To
see if cancer cells express also TA*p63 we performed
immunoprecipitation (IP) experiments with lysate from
the mesenchymal triple-negative breast cancer cell line
Sum159. Using two different p63 speciﬁc antibodies
(ab124762, Abcam; AHP1815, BioRad) for IP, we detected
a band with a molecular weight of ~75 kDa on western
blot (Fig. 6a). For further analysis, an IP-sample was
submitted to liquid-chromatography coupled to tandem
mass spectrometry (LC-MS/MS) following in-gel diges-
tion. Two independent experiments using two different
types of mass spectrometers relying on different frag-
mentation and detection approaches were performed. In
both analyses, we could clearly identify the two N-
terminal tryptic peptides of TA*p63 (MNFETSR and
CATLQYCPDPYIQR) with a very low posterior error
probability (PEP) and almost full fragmentation ladders
(Fig. 6b, Supplementary Fig. S7) revealing that TA*p63α is
indeed present in the Sum159 cell line.
To test whether TA*p63α can be activated in Sum159
cells by chemotherapeutic agents and induce apoptosis
we treated cells with 10 µM Dox. TA*p63α’s oligomeric
state shifted from the inactive, dimeric to the active,
tetrameric form as monitored by BN-PAGE (Fig. 6c).
Furthermore, the apoptosis marker cleaved PARP and
cleaved Caspase3 are detectable starting 4 h following
treatment (Supplementary Fig. S8). We also investigated
cell survival. Sum159 cells treated with Dox (1.5 µM) or
DMSO for 24 h and cultured for additional 24 h revealed
a clear decrease in cell density following Dox treatment
(Fig. 6d). These results suggest that TA*p63α in tumor
cells could be used as a tool to ﬁght these type of
cancer cells.
Discussion
The original function of the p53 protein family during
evolution was probably the protection of the genetic
quality in germ cells. More primitive organisms, such as
C. elegans25,26 and Nematostella vectensis27, express a p53
homologue in their germs cells that based on the presence
of a SAM domain is more closely related to p63 than to
p5328. In mammals p63 gets expressed in oocytes in the
diplotene phase of prophase I when cells have repaired
DNA double strand breaks inﬂicted by Spo11 as part of
the process of homologous recombination. Oocytes that
have not repaired these DNA double strand breaks will be
eliminated in a p63 dependent mechanism. For all
remaining oocytes that have successfully repaired the
DNA double strand breaks the continuously high level of
p63 during the following dictyate arrest stage constitutes a
constant threat. Consequently, the transcriptional activity
of p63 is very tightly regulated in germ cells. Inhibition is
based on blocking the tetramerization interface of the TD,
which in the p53 protein family consist of a dimer of
dimers29–32. This is achieved by a six-stranded antiparallel
β-sheet that is formed by the TID of both monomers and
a segment N-terminal to the DBD that adds two more
β-strands per monomer9. The TAD of TAp63α that
consists of a single helix stabilizes the closed conforma-
tion by binding to the TD as well8. This interaction
between the TAD and the TD is the weakest structural
element of the inhibitory complex due to a relatively fast
kinetic off-rate of the TAD9. A further stabilization of the
entire complex, which would result in a tighter regulation
of the transcriptional activity, can therefore only be
reached by modiﬁcation of the N-terminal elements. Such
a higher stability of the inhibitory complex is achieved by
the N-terminal extensions of the TA* and GTA isoforms.
There are two possible models how the N-terminal pep-
tides stabilize the dimeric conformation. In the ﬁrst, the
N-terminal extension acts as an additional “safe-lock”
function, binding to the same site in the TD as the TAD8
(Fig. 7a). In case of dissociation of the TAD from its
binding site a second peptide would be in close proximity
to prevent tetramerization by binding to the now vacant
site on the TD and thus keeping the original TA peptide
in close proximity for rebinding. In the second model, the
N-terminal peptides bind to additional binding sites,
building a “double-locked” dimeric conformation (Fig. 7b)
and keep the protein in a more tightly packed state.
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Both GTAp63α and TA*p63α can be converted into an
open tetrameric form by the same two kinases as TAp63α.
However, this process seems to be slower and does not
reach the same level of activated tetramers compared to
TAp63α. It is conceivable that effective activation of the
GTAp63α and TA*p63α isoforms requires the action of
an additional kinase since several potential phosphoryla-
tion sites are present in the N-termini of both isoforms.
Alternatively, the N-termini of both isoforms could also
(partially) occlude the kinase interaction sites. Further-
more, a faster degradation of the transcriptionally more
active TA* and GTA forms could also contribute to the
difference in dimer/tetramer ratio compared to TAp63α.
In the case of GTAp63α, activation was shown to involve
caspase-dependent cleavage of the SAM and TID14. A
similar processing of the p63 C-termini by caspases has
been suggested for TAp63α and ΔNp63α as well33.
In addition to their role in stabilizing the dimeric con-
formation the N-termini of TA*p63 and GTAp63 also
support the transcriptional activity. Both N-termini have
at least one further binding site for the Taz2 domain of
the co-activator p300, which usually binds to the TA
domain16. Consequently, in the active, tetrameric con-
formation there are at least eight interaction sites per
molecule compared to four in TAp63 resulting in an
increased afﬁnity to p300 (Fig. 7c).
The question remains why the biological functions of
the GTAp63α and TA*p63α require a tighter control of
their transcriptional activity compared to TAp63α in
oocytes. GTAp63α is expressed in mitotic spermatogo-
nia and at decreasing levels in suprabasal, meiotic
spermatocytes while haploid spermatozoa have lost
expression of all p63 isoforms14. Spermatogonia are
situated below the blood–testis barrier and comprise the
germ stem cell compartment. Monitoring the genetic
quality of these male germ stem cells is of critical
importance to preserve germ-line integrity and ensure
the evolutionary survival of a species. The very high
replication activity in male germ stem cells compared
with any other cell types (50–200 million spermatozoa
are produced per individual per day) combined with the
very long reproductive period in humanoid males might
be the reason for this special type of genetic quality
control. It was speculated that the incorporation of the
retroviral LTR into the p63 coding sequence was a cri-
tical event that made the long reproductive period in
humans possible14.
There are, however, distinct differences between the
function of TAp63α in the female germ-line and the
function of GTAp63α in male germ cells. While TAp63α
gets expressed after the end of the period of homologous
recombination and stays at high level throughout the cell
Fig. 6 TA*p63α is expressed in the triple-negative epithelial breast cancer cell line Sum159 and activated upon Dox treatment. a SDS-PAGE
followed by western blotting of immunoprecipitated TA*p63α in Sum159 lysate prior to MS analysis. Immunoprecipitation was performed with two
different p63 speciﬁc antibodies, AHP1815 (BioRad) and ab124267 (Abcam). For detection on WB, the p63α XP (D2K8X, cell signaling) antibody was
used. b Speciﬁc TA*-peptides were found in two independent IP-MS analyses of immunoprecipitated p63 from Sum159 cells. Immunoprecipitation
was performed with the p63 antibody ab124267 (Abcam). Two different types of mass spectrometers relying on different fragmentation and
detection approaches were used for the experiments (IT: ion trap, CID: collision induced dissociation, FT: Fourier transform, HCD: higher-energy
collisional dissociation). c BN-PAGE (3–12%) of Sum159 lysate followed by western blotting for TA*p63α. Sum159 cells were treated with 10 µM Dox
for different periods of time. Migration of the different oligomeric states is indicated by T (tetramer), D (dimer), and M (monomer). d Survival assay of
Sum159 cells. Cells were treated with 1.5 µM Dox or DMSO for 24 h (six-well plate) and cultured for additional 24–30 h. Sum159 cells were ﬁxed with
glutaraldehyde (6%) and stained with crystal violet (0.5%)
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cycle arrest phase, GTAp63α is mostly expressed in
mitotically dividing stem and progenitor cells. It seems to
be present also in cells undergoing homologous recom-
bination just before meiosis. How these cells manage to
suppress activation of GTAp63α triggered by the DNA
double strand breaks being created is currently not
known. The additional N-terminal domain might make
GTAp63α more resistant to phosphorylation triggered
activation. However, our experiments have shown that
GTAp63α can get activated by the combined action of the
Chk2 and CK1 kinases, following the mechanism seen in
TAp63α in oocytes. A lack of the essential kinases or the
presence of phosphatases might keep GTAp63α inactive.
The time spent in the meiotic stage also clearly differs
between the female and male germ cells. While oocytes
are arrested in prophase of meiosis I for up to 50 years
spermatocytes remain at the same stage only for hours.
How these vastly differing time frames inﬂuence the
genetic quality monitoring mechanisms remains to be
investigated.
Fig. 7 Model of the regulatory function of the N-terminal speciﬁc peptides in TA*p63α. Models are shown explicitly for TA*p63α but
represent GTAp63α as well. a In the ﬁrst model, TA*p63α’s and GTAp63α’s speciﬁc N-termini bind to the same interaction site as the TAD (red) on
the TD (cyan). Consequently, the dimeric conformation has an additional “safe lock”. In case of dissociation of the TAD, the TA*-GTA* peptide (blue-
orange) is able to keep the protein in its dimeric state and the TAD in close proximity for rebinding. b In the second model, TA*p63α’s and GTAp63α’s
speciﬁc peptides are binding in their inactive, dimeric state to a further interaction site independent of the TAD keeping p63 in a more tightly packed
state by building a “double lock” safety mechanism. c Schematic representation of the activity difference between the two oligomeric states of
TA*p63α (GTAp63α) and TAp63α. The dimeric conformation of TA*p63α shows a higher stability due to the additional stabilization of the N-terminal
peptides in comparison to TAp63α. The open, tetrameric state of TA*p63α, however, possess at least four further binding sites for the co-activator
p300, resulting in a greater transactivation potential. Consequently, the activity difference between the inactive and active state of TA*p63α (ΔTA*p63α,
black) is higher than the one of TAp63α (ΔTAp63α, gray)
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Our MS analysis has shown that TA*p63α is expressed
in the mesenchymal triple-negative breast cancer cell line
Sum159 together with a destabilizing mutant p53 form. In
principle destabilized p53 mutants (such as p53R175H)
can co-aggregate with p63 isoforms with an accessible TI
domain17 and such an interaction could inactivate tetra-
meric TA*p63α. In preliminary experiments, we could,
however, not see an interaction between both proteins in
Sum159 cells so far. Several other investigations have
shown that TAp63α is expressed in different cancer
types34. Why a cancer cell expresses a pro-apoptotic wild-
type member of the p53 protein family is not clear.
However of all possible isoforms the N-terminal elon-
gated TA*p63α is the one with the lowest basal tran-
scriptional activity but can be probably used as a tool to
induce apoptosis. If other cancer cells reported to express
TAp63α in reality express TA*p63α has to be determined.
Material and methods
Cell culture
The human osteosarcoma cell lines Saos-2, U2OS and
the breast cancer cell line Sum159, were cultured in
DMEM medium (with glutamine, Gibco) while the non-
small cell lung cancer cell line H1299 in RPMI medium
1640 (Gibco), respectively, containing 10% FBS (Capri-
corn Scientiﬁc) and 100mg/ml Penicillin/Streptomycin
(Gibco) at 37 °C and 5% CO2. Saos-2, U2OS and H1299
were obtained from ATCC. The Sum159 cell line was a
gift from Frank D. McKeon (Jackson Laboratory of
Genomic Medicine, Farmington, CT, USA). All cell lines
were regularly tested negative for mycoplasma con-
tamination using a PCR-based test.
Cloning
All constructs for transient mammalian cell transfection
were cloned in a pcDNA3 vector without or with an N-
terminal myc-tag. The following mutations were intro-
duced in the p63 gene: FWL (F16A, W20A, L23A; 5′GAA
TTC CTC AGT CCA GAG GTT GCC CAG CAT ATC
GCC GAT TTT GCC GAA CAG CCT ATA TGT TCA
GTT CAG3′), YF (Y18*A,F22*A; 5′CAG TAC TGC CCT
GAC CCT GCC ATC CAG CGT GCC GTA GAA ACC
CCA GCT CAT TTC 3′), WY (W31*A,Y35*A/W29′A,
Y33′A; 5′GAA ACC CCA GCT CAT TTC TCT GCC
AAA GAA AGT GCC TAC CGA TCC ACC GCC
TCC3′), YF WY (5′CAG TAC TGC CCT GAC CCT GCC
ATC CAG CGT GCC GTA GAA ACC CCA GCT CAT
TTC TCT GCC AAA GAA AGT GCC TAC CGA TCC
ACC GCC TCC3′), WFV (W9′A, F12′A, V15′A; 5′GTT
GGG AGC AGC GGG ATG CCA CAG CGG CCA CTA
AGG CCG GAA AGC CCT GTT TTG TTG AG3′), WFV
WY (5′GTT GGG AGC AGC GGG ATG CCA CAG
CGG CCA CTA AGG CCG GAA AGC CCT GTT TTG
TTG AGA CAC CAG CAC ACT TCA GTG CCA AAG
AAT CAG CCT ACC GCA GCA CCG CCT C3′), S582/
S583A (5′CAT CTC CTG CGG ACC CCA GCC GCC
GCC TCT ACA GTC AGT GTG G3′). In case of p53, the
DNA contact mutant R175H (5′CAT GAC GGA GGT
TGT GAG G CAC TGC CCC CAC CAT GAG CG3′) was
generated.
Generation of H1299 cells stably expressing p63α isoforms
For generation of stably expressing H1299 cells, the
PiggyBac Transposon System (System Bioscience) was
used. H1299 cells were transfected in a six-well plate
using the Qiagen Effectene kit according to manu-
facturer’s manual. Three hundred nanogram pBQM812A
(PB-Cuo-MCS-IRES-GFP-EF1α-CymR-Puro Inducible
cDNA Cloning and Expression Vector) containing p63α
and 100 ng pB200A (PiggyBac Transposase expression
vector) were used for transfection. One day after trans-
fection, cells were reseeded in 10 cm dishes. Two days
after transfection, H1299 cells were selected using pur-
omycin (5 µg/mL) until single colonies emerge (about
10–14 days). Single colonies (four for each construct)
were isolated, expanded and tested for stable inducible
expression of p63 on WB and for oligomeric state on BN-
PAGE. For induction, a self-prepared 10,000x Cumate
(Sigma–Aldrich) solution in ≥99.8% ethanol (Carl Roth
GmbH) was used. For further experiments, one clone of
each construct was chosen.
Transactivation assay
Cells were transfected in a 12-well plate with same
amount per plasmid (pcDNA3, pGL3 and pRL-CMV)
using the Qiagen Effectene kit according to manu-
facturer’s manual and grown for 24 h. The transactivation
assays were performed using the Promega Dual-Glo
Luciferase reporter assay kit. Cells were washed with
PBS (Gibco), harvested and assayed for ﬁreﬂy and renilla
activity in a 96-well plate in quadruplicates. The ratio of
the ﬁreﬂy to renilla signal was determined and normalized
to empty vector. The remaining sample was used for
determination of expression levels via western blot using
the BioRad system. Three independent experiments have
been performed for each transactivation assay. For sta-
tistical analysis, P-values were calculated in an unpaired t-
test using the GraphPad t-test calculator (https://www.
graphpad.com/quickcalcs/ttest1/?Format= SD).
Western blotting
4–15 or 7.5% SDS–PAGE Mini-PROTEAN TGX gels
(BioRad) were blotted using the semidry Trans-Blot
Turbo Transfer system (BioRad).The following anti-
bodies were prepared in 5% milk in TBS-T and incubated
overnight at 4 °C: anti-Myc (1:1000, clone 4A6, Millipore),
anti-p63 (1:2500, ab124762, Abcam), anti-p63α XP
(1:1000, D2K8X, Cell Signaling), anti-GAPDH (1:20,000,
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clone 6C5, Merck), anti-p53 (1:500, DO-1, Santa Cruz),
anti-PARP (1:1000, 9542, Cell Signaling), anti-cleaved
caspase3 (1:1000, 5A1E,Cell Signaling), and anti-vinculin
(1:1000, clone 7F9, Santa Cruz). Secondary antibodies,
used for detection, were also prepared in 5% milk in TBS-
T and incubated for 1 h at RT (goat anti-mouse HRP,
1:5000, A9917, Sigma–Aldrich; goat anti-rabbit HRP,
1:2000, Jackson Immuno Research Europe Ltd.,
111–035–144). Quantiﬁcation of western blot signals was
performed by using ImageJ.
Blue-Native PAGE
H1299 cells were transfected using the Qiagen Effectene
kit according to the manufacturer’s manual in a 12-well
plate or H1299 cells stably expressing p63 isoforms were
used. Cells were harvested and lysed in NP lysis buffer
(20 mM Tris, 150mM NaCl, 2 mM MgCl2, 20 mM
CHAPS, 1 mM DTT, complete protease inhibitor cocktail
(Roche), PhosSTOP (Roche) pH 7.4 or pH 8.0). Benzonase
(Merck) was added and samples were lysed on ice for 1 h.
BN-PAGE (3–12%, Thermo Fisher Scientiﬁc) was per-
formed and blotted as previously described17,35. Protein
levels loaded on BN-PAGE were adjusted to equal p63
amounts by prior western blot analysis. SDS-PAGE to
detect phosphoshifts were not input adjusted.
Urea assay Blue-Native PAGE
H1299 cells were transfected using the Qiagen Effectene
kit according to the manufacturer’s manual in a 10 cm
dish, grown for about 24 h, harvested and collected in NP
lysis buffer without detergent (20 mM Tris, 150mM
NaCl, 2 mM MgCl2, 1 mM DTT, complete protease
inhibitor cocktail (Roche), PhosSTOP (Roche) pH 7.4).
Samples were lysed via three freeze and thaw cycles. After
centrifugation, Benzonase (Merck Millipore) was added
and incubated 1 h on ice. Samples were split and incu-
bated with different urea concentration for 1 h on ice. An
equal volume of NP lysis buffer was added containing the
two-fold concentration of CHAPS (20 mM Tris, 150mM
NaCl, 2 mM MgCl2, 40 mM CHAPS, 1 mM DTT, com-
plete protease inhibitor cocktail (Roche), PhosSTOP
(Roche) pH 7.4) and incubated for about 10min. After-
wards, 3× NP sample buffer (60% Glycerol, 15 mM Coo-
massie G250) was added and the sample was loaded on
the gel. BN-PAGE (3–12%, Thermo Fisher Scientiﬁc) was
performed and blotted as previously described13,35.
Size exclusion chromatography (SEC)
N-terminal myc-tagged p63 isoforms and mutants were
expressed in vitro using rabbit reticulo lysate expression
system (Promega) as described previously8. Lysates were
centrifuged at 16,100 × g for 15min at 4 °C. Analytical
SEC was performed at the Äkta puriﬁer system in phos-
phate buffer (50mM sodium phosphate pH 7.8, 100mM
NaCl) at 4 °C using a Superose 6 3.2/300 column (GE
Healthcare) (injection volume 50 μL; ﬂow rate 50 μL/min;
fraction size 50 μL). The SEC fractions were collected and
analyzed via western blotting.
Staining
H1299 cells were transfected using the Qiagen Effectene
kit according to the manufacturer’s manual in a 12-well
plate seeded on glass slides. Twenty-four hour after
transfection, cells were washed three times with PBS, ﬁxed
with 3.7% formaldehyde for 10min and washed again
three times with PBS. Cells were permeabilized by per-
meabilization buffer (PBS with 0.1% Triton X-100) for
15min and blocked for 30min (1% BSA, 0.1% Tween-20
in PBS). Anti-Myc (1:500, A190-104A, Bethyl) and anti-
β-actin (1:100, clone C4, Santa Cruz) antibody were
incubated overnight at 4 °C in blocking buffer. Slides were
washed three times with PBSt (containing 0.1% Tween-
20), incubated with secondary antibody (1:1000 in
blocking buffer, donkey anti-mouse Alexa 488, donkey
anti-goat Alexa 568, Thermo Fisher Scientiﬁc) for 1 h at
RT in the dark and washed three times. Coverslips were
mounted using Mowiol (Carl Roth GmbH) mounting
medium, including DAPI (Thermo Fisher Scientiﬁc) and
dried for 1–2 days. The mounting medium was prepared
as described in CSH protocols (http://cshprotocols.cshlp.
org/content/2006/1/pdb.rec10255). Pictures were taken
using the confocal microscope Leica TCS SP5.
Fluorescence anisotropy
The p300 Taz2 domain was expressed and puriﬁed as
described before16. The N-terminal ﬂuorescein labeled
peptides TA*-GTA* and GTA-GTA* were ordered at
Peps4LS (Heidelberg, Germany). Hundred nanomolar
peptide was used for the measurements with increasing
concentration of Taz2. The experiment was performed at
22 °C using a FP-6500 spectrometer (Jasco, Gross-
Umstadt, Germany) and a 115F-QS cuvette (Hellma,
Müllheim). The results were ﬁtted with GraphPad Prism 5
using a two site speciﬁc binding ﬁt.
Immunoprecipitation
For each MS sample, 20 × 15 cm dishes of 80%-con-
ﬂuent breast cancer cell lines were harvested and pooled.
Cells were resuspended in lysis buffer (50 mM Tris,
150mM NaCl, 1 mM DTT, 2 mM MgCl2, 0.5% NP-40,
complete protease inhibitor cocktail (Roche), PhosSTOP
(Roche), pH 8.0). Benzonase (Merck) was added and
samples were lysed for about 1½ h at 4 °C. Lysates were
cleared via centrifugation (16,100 × g, 15 min, 4 °C) and
supernatant was diluted with IP washing buffer (50 mM
Tris, 150 mM NaCl, 0.1% Tween-20, pH 7.8). The lysate
was pre-cleared with Dynabeads protein G (Thermo
Fisher Scientiﬁc) for 1 h. Afterwards, the diluted lysate
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was split and 6 µg anti-p63 antibody (ab124762, Abcam)
or rabbit gamma globulin/IgG (Thermo Fisher Scien-
tiﬁc) was added and incubated overnight at 4 °C. The
next day, Dynabeads protein G (Thermo Fisher Scien-
tiﬁc) were added for 2–3 h at 4 °C. Beads were washed
eight times, transferred into a new tube and eluted with
1× NuPAGE LDS sample buffer (Thermo Fisher Scien-
tiﬁc) supplemented with 50 mM DTT by incubating at
70 °C for 10 min. The supernatant was transferred in to a
new tube.
Cell survival assay
Sum159 cells were seeded in a six-well plate. Two days
after seeding, cells were treated either with 1.5 µM Dox or
DMSO for 24 h. The medium was changed and cells were
cultured for additional 24–30 h. Afterwards, cells were
washed three times with PBS and the ﬁxation and staining
solution (0.5% crystal violet, 6% glutaraldehyde) was
incubated 1–2 h at RT. The solution was aspirated and the
ﬁxed cells were washed about ﬁve times with H2O and
dried for 1–2 days at RT.
MS sample preparation
Immunoprecipated p63 of the Sum159 breast cancer
cell line was applied on SDS-PAGE Mini-PROTEAN gel
(BioRad) and silver stained (SilverQuest Silver Staining
Kit, ThermoFisher Scientiﬁc) for MS analysis. Stained
bands were isolated and destained. Proteins were reduced
with 10mM DTT for 45min at 56 °C and alkylated with
55mM Iodoacetamide for 30min at RT under light-
protection. After digestion with Trypsin at 37 °C over-
night, tryptic peptides were extracted from the gel pieces
consecutively with 30% acetonitrile (ACN) containing 3%
Triﬂuoroacetic acid (TFA), then 80% ACN containing
0.1% TFA and ﬁnally 100% ACN for 30min each.
Extraction solutions were combined and dried by vacuum
centrifugation before reconstitution in 0.1% Formic acid
for LC-MS/MS analysis.
LC-MS analyses
For the ﬁrst MS experiment, peptides were analysed on
an Orbitrap Elite mass-spectrometer coupled to an easy
nLC II (ThermoFisher Scientiﬁc) using a 20 cm long,
75 µm ID fused-silica column, which has been packed in
house with 3 µm C18 particles (ReproSil-Pur, Dr. Maisch),
and kept at 45 °C using an integrated column oven
(Sonation). Peptides were eluted by a non-linear gradient
from 8–40% acetonitrile over 19min and directly sprayed
into the mass-spectrometer via a nanoFlex ion source
(ThermoFisher Scientiﬁc) at a spray voltage of 2.3 kV. Full
scan MS spectra (300–2000 m/z) were acquired at a
resolution of 120,000 at m/z 200, a maximum injection
time of 100ms and an AGC target value of 1 × 106
charges. Up to 20 most intense peptides per full scan were
isolated in the ion trap using a 2 Th window and frag-
mented using collision induced dissociation (CID, nor-
malized collision energy of 35). MS/MS spectra were
acquired in rapid mode using a maximum injection time
of 25ms and an AGC target value of 5 × 103. Ions with
charge states of 1 and >6 as well as ions with unassigned
charge states were not considered for fragmentation.
Dynamic exclusion settings were 1 repeat count and 30 s
repeat duration as well as an exclusion duration of 90 s in
order to minimise repeated sequencing of already
acquired precursors.
The second experiment was analysed on a Q Exactive
HF coupled to an easy nLC 1200 (ThermoFisher Scien-
tiﬁc) using a 20 cm long, 75 µm ID fused-silica column
packed in house with 1.9 µm C18 particles (Reprosil pur,
Dr. Maisch), and kept at 50 °C using an integrated column
oven (Sonation). Peptides were eluted by a non-linear
gradient from 4–24% acetonitrile over 24min and directly
sprayed into the mass-spectrometer equipped with a
nanoFlex ion source (ThermoFisher Scientiﬁc). Full scan
MS spectra (350–1650m/z) were acquired at a resolution
of 60,000 at m/z 200, a maximum injection time of 20ms
and an AGC target value of 3 × 106 charges. Up to 10 most
intense peptides per full scan were isolated using a 1.4 Th
window and fragmented using higher-energy collisional
dissociation (normalised collision energy of 27). MS/MS
spectra were acquired with a resolution of 30,000, a
maximum injection time of 110ms and an AGC target
value of 1 × 105. Single charged ions, ions with a charge
state above 5 and ions with unassigned charge states were
not considered for fragmentation and dynamic exclusion
was set to 20 s.
Mass spectrometry data processing
MS raw data processing was performed with MaxQuant
(v 1.6.5.0) applying default parameters. Acquired spectra
were searched against the human reference proteome
(Taxonomy ID 9606) downloaded from UniProt
(21–11–2018; 94731 sequences including isoforms) and a
collection of common contaminants (244 entries) using
the Andromeda search engine integrated in Max-
Quant36,37. Identiﬁcations were ﬁltered to obtain false
discovery rates (FDR) below 1% for both peptide spectrum
matches (PSM; minimum length of 7 aa) and proteins
using a target-decoy strategy38.
Predictions—helical wheel and secondary structure
For secondary structure prediction of the N-terminus the
Phyre (Protein Homology/analogy recogniction engine V
2.0, http://www.sbg.bio.ic.ac.uk/phyre2)20 server was used.
Based on this results, a helical wheel projection was created
by NetWheels (http://lbqp.unb.br/NetWheels).
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